Entity family
Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.
This disease is selected. Its supporting articles are shown below.
…ckground Patients with high-risk, relapsed/refractory pediatric solid tumors continue to have poor clinical outcomes. NK cell immunotherapie…
…enance at 480 mg every 4 weeks ( figure 1). Patients presenting solid tumors with known sensitivity to PD-1/PD-L1 blockade were treated in t…
…n-based cancer vaccines offer a promising approach for treating solid tumors, but clinical efficacy has been limited by two major challenges…
…en G (HLA-G), a non-classical MHC class I molecule expressed on solid tumors, is known to drive immune suppression, promote cancer cell immu…
…ion by immunohistochemistry (10% ≥ 1+); ovarian, pancreatic and mesothelioma cancer patients will not require prospective screening due to t…
…safety, pharmacokinetics and pharmacodynamics, in patients with solid tumors as a monotherapy and in combination with anti-PD-1 antibody pem…
…ong them, HERV-K stands out due to its aberrant reactivation in solid tumors while remaining silent in healthy tissues, positioning it as a …
…utic ultrasound for multimodal cancer treatment: a spotlight on breast cancer. Annual Review of Biomedical Engineering 2025;27:371–402.DeWitt…
…gh dihydroorotate dehydrogenase (DHODH) inhibition, sensitizing solid tumors to immune checkpoint blockade.12 Furthermore, to increase low f…
…Background Oncogenic RAS mutations are prevalent in solid tumors and play a central role in driving immune evasion. While RAS in…
… individually and in combination – has activity across multiple solid tumors. However, not all patients respond, responses can be of short d…
… novel therapeutic approaches targeting CX3CL1, particularly in cold tumors where tumor cells produce high levels of CX3CL1.Ethics Approval…